[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vanda Pharmaceuticals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":410},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,70,93,121,147,174,192,218,242,263,295,320,341,362,383],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100609976",false,"NCT07221578","Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder","Inclusion Criteria:\n\n1. Ability and willingness to provide written informed consent.\n2. Male and female subjects aged 18-65 years, inclusive.\n3. Current diagnosis of social anxiety disorder.\n4. Liebowitz Social Anxiety Scale total score ≥60.\n5. Public Speaking Anxiety Scale total score ≥60.\n6. Hamilton Depression Rating Scale score ≤18.\n\nExclusion Criteria:\n\n1. Suicide attempts and\u002For suicidal ideation in the past 2 years or currently at risk of suicide in the opinion of the investigator.\n2. History of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders, obsessive-compulsive disorder, or autism spectrum disorder.\n3. Posttraumatic stress disorder or an eating disorder in the past 6 months.\n4. Substance or alcohol use disorder in the past 6 months or positive in drug\u002Falcohol screening.\n5. Psychotherapy in the past 6 months.\n6. Psychotropic medication in the past 2 months.\n7. Current or planned pregnancy or nursing during the trial period.\n8. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, or interference with study objectives.","ALL","18 Years","65 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.",[26],"Social Anxiety Disorder (SAD)",[28,29,30,31,32],"Social Anxiety Disorder","Social Phobia","SAD","Public Speaking Anxiety","Performance Anxiety","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2025-09-22",{"date":41,"type":20},"2027-04",{"name":43,"class":44},"Vanda Pharmaceuticals","INDUSTRY",31,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100620776","NCT07362017","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug",{"count":53,"type":20},300,[23],"An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",[57],"Moderate-to-severe Chronic Plaque Psoriasis",[59,60],"psoriasis","Moderate-to-severe chronic plaque psoriasis","2026-06-10",{"date":63,"type":37},"2026-06-11",{"date":65,"type":37},"2026-02-17",{"date":67,"type":20},"2028-12",{"name":43,"class":44},4,{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":10,"sex":15,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100589396","NCT06953869","Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required).\n* Confirmed clinical diagnosis of insomnia disorder\n* Males and Females between 2 and 17 years, inclusive.\n* The sleep disturbance must not be a result of another medication.\n\nExclusion Criteria:\n\n* Inability to dose daily with tasimelteon or previous intolerance to tasimelteon.\n* Indication of impaired liver function.\n* Pregnant or lactating females.\n* A positive test for drugs of abuse.","2 Years","17 Years",{"count":79,"type":20},420,[23],"This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.",[83],"Insomnia Disorder","2026-06-03",{"date":86,"type":37},"2026-06-05",{"date":88,"type":37},"2025-04-21",{"date":90,"type":20},"2028-01",{"name":43,"class":44},35,{"id":94,"slug":4,"hasResults":10,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100627269","NCT07446439","A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers","Inclusion Criteria:\n\n* Body Mass Index ≥ 25 and \\\u003C 40 kg\u002Fm\\^2\n* No serious medical problems or chronic diseases, specifically no type I or type II diabetes\n\nExclusion Criteria:\n\n* Another disorder that contributes to gastrointestinal symptoms\n* History of intolerance and\u002For hypersensitivity to NK-1 receptor antagonists\n* History of intolerance and\u002For hypersensitivity to GLP-1 receptor agonists\n* Exposure to any investigational medication within the past 60 days",true,{"count":101,"type":20},280,[23],"The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.",[105,106],"Nausea and Vomiting","Obesity",[108,109,110,111],"GLP-1R agonist","Semaglutide","Nausea","Vomiting","2026-04-14",{"date":114,"type":37},"2026-04-20",{"date":116,"type":37},"2026-03-27",{"date":118,"type":20},"2026-12-01",{"name":43,"class":44},10,{"id":122,"slug":4,"hasResults":10,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100350139","NCT03838926","Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n* Subject is ≥ 18 years at the time of signing informed consent;\n* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;\n* Presence of measurable or evaluable disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n* Contraceptives or other approved avoidance of pregnancy measures\n\nExclusion Criteria:\n\n* Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;\n* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);\n* Undergone major surgery ≤ 2 weeks prior to starting study drug;\n* Evidence of mucosal or internal bleeding;\n* Impaired cardiac function or conduction defect;\n* Concurrent severe and\u002For uncontrolled medical conditions",{"count":127,"type":20},42,[129],"PHASE1","The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.",[132],"Relapsed or Refractory Hematologic Malignancies",[134,135,136,137],"Hematologic","Malignancies","Cancer","Blood","2026-03-12",{"date":140,"type":37},"2026-03-16",{"date":142,"type":37},"2018-09-27",{"date":144,"type":20},"2027-12",{"name":43,"class":44},11,{"id":148,"slug":4,"hasResults":10,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100599874","NCT07090161","Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","Inclusion Criteria:\n\n* SiSBP \\>\u002F= 130 mmHg despite \\>8 weeks treatment w\u002F 1 or more antihypertensive therapies\n\nExclusion Criteria:\n\n* Confirmed Grade 3\u002Fsevere hypertension (SiSBP \\>\u002F= 180 mmHg, SiDBP \\>\u002F= 120 mmHg), unstable cardiac disease, renal insufficiency",{"count":154,"type":20},240,[156],"PHASE2","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension",[159,160],"Hypertension","Uncontrolled Hypertension",[162,163,164],"iloperidone","hypertension","uncontrolled hypertension","2026-02-25",{"date":167,"type":37},"2026-02-27",{"date":169,"type":37},"2025-09-15",{"date":171,"type":20},"2026-11",{"name":43,"class":44},28,{"id":175,"slug":4,"hasResults":10,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100579880","NCT06830044","Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder","A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","Inclusion Criteria:\n\n* Male or female patient 18 to 65 years of age, inclusive;\n* Meets DSM-5-TR criteria for MDD\n* Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ)\n\nExclusion Criteria:\n\n* Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment",{"count":19,"type":20},[23],"The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder",[184],"Major Depressive Disorder (MDD)",{"date":167,"type":37},{"date":187,"type":37},"2025-03-03",{"date":189,"type":20},"2028-03",{"name":43,"class":44},38,{"id":193,"slug":4,"hasResults":10,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},"100590019","NCT06961968","Randomized Withdrawal Study in Patients With Schizophrenia","A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection","Inclusion Criteria:\n\n* Males or females 18 to 65 years of age (inclusive)\n* Diagnosed with schizophrenia per DSM-5 criteria\n* In need of ongoing psychiatric treatment\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months",{"count":199,"type":20},400,[23],"The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.",[203],"Schizophrenia",[203,205,206,207,208],"Antipsychotic Agents","Iloperidone","Long-Acting Injection","Randomized Withdrawal","2026-01-09",{"date":211,"type":37},"2026-01-12",{"date":213,"type":37},"2025-05-14",{"date":215,"type":20},"2027-11",{"name":43,"class":44},22,{"id":219,"slug":4,"hasResults":10,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100412617","NCT04652882","Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)","A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Participants With Delayed Sleep-Wake Phase Disorder (DSWPD)","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent.\n* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).\n* Men or women between 18 - 75 years, inclusive.\n* Body Mass Index (BMI) of ≥ 18 and ≤ 35 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* Exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months.\n* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.\n* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.\n* A positive test for substances of abuse.\n* Current tobacco user.","75 Years",{"count":226,"type":20},70,[23],"This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.",[230,231,232],"Sleep Wake Disorders","Sleep Disorders, Circadian Rhythm","Chronobiology Disorders","2025-11-24",{"date":235,"type":37},"2025-12-02",{"date":237,"type":37},"2020-12-09",{"date":239,"type":20},"2026-06",{"name":43,"class":44},17,{"id":243,"slug":4,"hasResults":10,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":262},"100606707","NCT07179055","An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye","An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Be at least 18 years of age of either gender and any race.\n* Provide written informed consent and sign the HIPAA form.\n* Be willing and able to follow all instructions and attend all study visits.\n\nExclusion Criteria:\n\n* Use of any of the disallowed medications during the washout and study period.",{"count":249,"type":20},160,[156],"The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.",[253],"Dry Eye","2025-09-10",{"date":256,"type":37},"2025-09-17",{"date":258,"type":20},"2025-10",{"date":260,"type":20},"2026-09",{"name":43,"class":44},5,{"id":264,"slug":4,"hasResults":10,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":269,"enrollmentInfo":4,"targetDuration":4,"studyType":270,"phases":4,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":289,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":293,"locationsCount":294},"100398963","NCT04474990","Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","Inclusion Criteria:\n\n* Identified subject who requested expanded access\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Patient does not qualify for or does not have access to other clinical trials with tradipitant;\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits;\n* Exposure to any investigational medication in the past 60 days other than tradipitant\n* Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year\n* Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit ratio to treatment;","70 Years","EXPANDED_ACCESS","Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant",[273,274],"Gastroparesis","Diabetic Gastroparesis",[276,277,278,279,280,281,282,283,284,285,286,287,288],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","expanded access","AVAILABLE","2025-08-18",{"date":292,"type":37},"2025-08-24",{"name":43,"class":44},15,{"id":296,"slug":4,"hasResults":10,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":10,"sex":15,"minAge":301,"maxAge":77,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},"100489090","NCT05648591","Safety and Tolerability of Open-Labeled Iloperidone in Adolescents","Open-label Safety Study of a 1-year 8 to 24 mg\u002FDay Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder","Inclusion Criteria:\n\n* Patient is willing and able to provide assent and willing to complete all aspects of the study\n* Patient's parent or legal guardian willing and able to provide consent\n* Male or female patients 12 through 17 years of age (inclusive)\n* Clinical diagnosis of either schizophrenia or bipolar I disorder\n\nExclusion Criteria:\n\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* A positive test for drugs of abuse","12 Years",{"count":303,"type":20},100,[305],"PHASE4","To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.",[203,308],"Bipolar I Disorder",[310],"fanapt","2025-02-27",{"date":313,"type":37},"2025-03-04",{"date":315,"type":37},"2023-05-24",{"date":317,"type":20},"2026-11-30",{"name":43,"class":44},9,{"id":321,"slug":4,"hasResults":10,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":269,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},"100580381","NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)",{"count":303,"type":20},[23],"This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[330,274,273],"Idiopathic Gastroparesis",[276,277,278,279,280,281,282,283,284,285,286,287],"2025-02-14",{"date":334,"type":37},"2025-02-20",{"date":336,"type":37},"2024-01-09",{"date":338,"type":20},"2025-12",{"name":43,"class":44},3,{"id":342,"slug":4,"hasResults":10,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":224,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},"100569988","NCT06701396","Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","A Double-Blind, Randomized, Two-Period Crossover Study to Evaluate the Effects of Tasimelteon Vs. Placebo in Subjects with Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent.\n* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).\n* Carrier of CRY1Δ11 variant.\n* Men or women between 18 - 75 years, inclusive.\n* Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.\n* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.\n* A positive test for substances of abuse.\n* Current tobacco user.",{"count":348,"type":20},60,[23],"This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.",[230,231,232,352],"Gene Mutations and Other Alterations Nec","2024-11-19",{"date":355,"type":37},"2024-11-22",{"date":357,"type":37},"2024-10-08",{"date":359,"type":20},"2025-06-30",{"name":43,"class":44},1,{"id":363,"slug":4,"hasResults":10,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":10,"sex":15,"minAge":368,"maxAge":17,"enrollmentInfo":369,"targetDuration":4,"studyType":371,"phases":4,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":361},"100297645","NCT03154697","Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances","Development of Clinical Database of Individuals With Smith-Magenis Syndrome","Inclusion Criteria:\n\n* Parent or legal guardian of individual with Smith-Magenis Syndrome\n\nExclusion Criteria:\n\n* Not legal guardian of individual with SMS","3 Years",{"count":370,"type":20},1000,"OBSERVATIONAL","This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.",[374],"Sleep Disturbances in Smith-Magenis Syndrome","2024-03-19",{"date":377,"type":37},"2024-03-20",{"date":379,"type":37},"2016-01",{"date":381,"type":20},"2030-12",{"name":43,"class":44},{"id":384,"slug":4,"hasResults":10,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":371,"phases":4,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":361},"100147817","NCT01195558","Patient Registry of Blind Subjects With Sleep-related Problems","Development of a Patient Registry of Blind Subjects With Sleep-related Problems","Inclusion Criteria:\n\n1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.\n2. Subjects must be blind.\n3. Subjects must have some self-described problem with sleep or daytime sleepiness.",{"count":390,"type":20},10000,"Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.",[393],"Sleep-wake Disorder in Blind Individuals",[395,396,397,398,399,400,401],"Non-24","N24HSWD","Blindness","Sleep","Wake","Circadian Rhythm","Nap","2020-06-22",{"date":404,"type":37},"2020-06-24",{"date":406,"type":4},"2010-04",{"date":408,"type":20},"2030-04",{"name":43,"class":44},""]